^{8th International Conference on} Clinical Nutrition December 8-10, 2016 Dubai, UAE

Monica Rosa Loizzo is Senior Department of Pharmacy, Health Science and Nutrition of University of Calabria. She is Professor in Food Science Technology and in Funcional Food. \r\nShe is author/co-author of 139 publications in international journal, 74 communications at national and international congress and 8 Chapter in book series. She is referee of several international journals and Institutions. Her h index is 25. She enabling National Scientific Achievement to become Associate Professor in 07/F1 (SSD AGR/15) and 03/D1 (SSD CHIM/10) for years 2014-2018 \r\n

Calabria (South of Italy) is around a quarter of the Italian Citrus production. The Calabria Clementine IGP (Citrus × clementina) is a hybrid between a Mediterranean Citrus ×deliciosa and a sweet orange. C. × clementina are grown in the province of Cosenza and are appreciated for the sweetness characteristics and the full taste and aroma made pleasant by the absence of seeds within the pulp. The nutritional interest in the significance of free radicals as a risk factor for the incidence of degenerative diseases is only acknowledged for one or two decades. One of the possibilities of ‘fighting’ free radicals is through the intake of antioxidants. C. × clementina juice obtained by fruits at fully maturity stage was investigated for its HPLC flavonoids profile and health properties. The quality parameters, including pH, total soluble solids, and ascorbic acid content were also determined. The radical scavenging potential were investigated by using ABTS and DPPH test. Among identified flavonoids neohesperidin (116.5 g/mL) and hesperidin (55.2 g/mL) were the main abundant compounds followed by narirutin (9.9 g/mL). Juice showed a potent radical scavenging ability in both assay with percentage of inhibition of 74.9 and 90.4% for ABTS and and DPPH test, respectively. The C. × clementina juice radical scavenging ability could be related with its great content of bioactive compounds.

Sarah Farid Mohamed Fahmy is a PhD student and Assistant Lecturer in Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. She has published two papers in the field of autism

Autistic spectrum disorder is a neurodevelopmental disorder with an unknown and somewhat controversial etiology. Vitamin D deficiency has been proposed as an important key player in the development and progression of autism spectrum disorders (ASDs) yet no prior double blinded trials have been conducted. It remains under debate whether children with autism should be supplemented with high doses of vitamin D to improve their symptoms. ASD patients were randomized in a double blinded placebo controlled trial to receive either 1000 international units of vitamin D per day for 3 month, followed by 1000 international units per 25 pounds per day (average dosing was 2800 IU/day) for another 3 months (n=22) or placebo (n=20). The primary outcome measures were changes in Childhood autism rating scale (CARS) and Autism treatment evaluation checklist (ATEC) scores. Secondary outcome measures were the changes in serum vitamin D levels as well as treatment emergent side effects. After 6 months of therapy, there were statistically significant improvements in CARS (4 points) and ATEC overall scores (16 points) in vitamin D group compared to placebo (p<0.001) with 31.8% of patients shift from severe range to mild-moderate range and 63.3% of patients reached the cut-off point of 30. There were no correlations between serum vitamin D levels and either CARS or ATEC scores were found. Finally, Vitamin D supplementation was tolerable and significantly improved clinical measurements of ASD severity